Patents by Inventor Suizhao Wang

Suizhao Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Skin punch biopsy and wound-debridgement training model
    Patent number: 10729650
    Abstract: A method of preparing a wound model. The method includes simulating a non-healing wound edge, simulating eschar, simulating a fibrin layer, simulating biofilm, and simulating foreign debris.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: August 4, 2020
    Assignee: United States of America as represented by the Secretary of the Air Force
    Inventors: Thomas Shaak, Suizhao Wang, Joseph Harre
  • NON-TOXIC VEHICLE TO SOLUBILIZE, DELIVER, AND OBTAIN BIOLOGICAL ACTIVITY OF STEROID HORMONES AT CELL, TISSUE, AND ORGAN TARGETS, IN VITRO AND IN VIVO
    Publication number: 20190388349
    Abstract: A non-toxic vehicle for hormone therapy. The non-toxic vehicle includes a cationic lipid or a neutral lipid and polyethylene glycol.
    Type: Application
    Filed: August 30, 2019
    Publication date: December 26, 2019
    Applicant: Government of the United States as Represented by the Secretary of the Air Force
    Inventors: Thomas Shaak, Suizhao Wang
  • TREATMENT OF TRIPLE NEGATIVE BREAST CANCER UTILIZING ANDROST-5-ENE-3b,17b-DIOL (b-AED), ANDROST-5-ENE-3b,7b,17b-TRIOL (b-AET) AND ESTRADIOL (E2)
    Publication number: 20180207177
    Abstract: A hormone modulator for causing cellular apoptosis in triple-negative breast cancer cells. The hormone modulator includes at least one of ?5-androsten-3?,17?-diol and ?5-androsten-3?,7?,17?-triol and estradiol.
    Type: Application
    Filed: January 19, 2018
    Publication date: July 26, 2018
    Applicant: Government of the United States as Represented by the Secretary of the Air Force
    Inventors: Thomas Shaak, Suizhao Wang
  • NON-TOXIC VEHICLE TO SOLUBILIZE, DELIVER, AND OBTAIN BIOLOGICAL ACTIVITY OF STEROID HORMONES AT CELL, TISSUE, AND ORGAN TARGETS, IN VITRO AND IN VIVO
    Publication number: 20180207097
    Abstract: A non-toxic vehicle for hormone therapy. The non-toxic vehicle includes a cationic lipid or a neutral lipid and polyethylene glycol.
    Type: Application
    Filed: January 19, 2018
    Publication date: July 26, 2018
    Applicant: Government of the United States as Represented by the Secretary of the Air Force
    Inventors: Thomas Shaak, Suizhao Wang
  • SKIN PUNCH BIOPSY AND WOUND-DEBRIDGEMENT TRAINING MODEL
    Publication number: 20180211566
    Abstract: A method of preparing a wound model. The method includes simulating a non-healing wound edge, simulating eschar, simulating a fibrin layer, simulating biofilm, and simulating foreign debris.
    Type: Application
    Filed: January 19, 2018
    Publication date: July 26, 2018
    Applicant: Government of the United States as Represented by the Secretary of the Air Force
    Inventors: Thomas Shaak, Suizhao Wang, Joseph Harre
  • PORCINE IMMUNE MODULATION MODEL
    Publication number: 20180207264
    Abstract: A method of modulating an immune response. The method includes administering a treatment comprising delta 5-androsten-3B, 17B-diol, delta 5-androsten-3B, 7B, 17B-triol, or both.
    Type: Application
    Filed: January 19, 2018
    Publication date: July 26, 2018
    Applicant: Government of the United States as Represented by the Secretary of the Air Force
    Inventors: Thomas Shaak, Suizhao Wang, Joseph Harre
  • Method of Cancer Treatment with Antagonists of FAS Inhibitors
    Publication number: 20100266577
    Abstract: In one embodiment, the present invention relates to a method of treating a cancer characterized by inhibition of Fas-mediated apoptosis, comprising administering to a patient suffering from the cancer a pharmaceutically-effective amount of a composition comprising a peptide that competitively antagonizes at least one protein-Fas binding selected from the group consisting of herpes virus 8 protein K1 binding to Fas, CD74 binding to Fas, and pi 00 binding to Fas. In a further embodiment, the peptide is selected from the group consisting of peptides having from about 15 to about 35 amino acid residues and comprising at least a portion of the immunoglobulin domain of K1, peptides having from about 15 to about 35 amino acid residues and comprising at least fifteen consecutive amino acid residues among positions 50-120 of CD74, LVTLLLAGQ ATT A YFL YQQQ, LYQQQGRLDKLTVTSQNLQL, QNLQLENLRMKLPKPPKPVS, and PKPVSKMRMATPLLMQALPM.
    Type: Application
    Filed: July 23, 2008
    Publication date: October 21, 2010
    Inventors: Felipe Samaniego, Suizhao Wang, Shu Wang